drugset / Trial / NCT04589026
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
Timeline
- Start
- 2020-10-21
- Primary completion
- 2021-05-06
- Completion
- 2021-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Secukinumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.